ReviewHepatic oncology2026
Patient characteristics to guide personalized treatment decisions and prognostication in hepatocellular carcinoma.
Review in Hepatic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality and arises predominantly in cirrhotic livers, making prognosis and treatment response highly dependent on hepatic reserve and comorbidity. With multiple first-line immunotherapy and anti-VEGF based regimens, real-world decision making requires individualized selection integrating multiple patient related factors including liver function, bleeding risk, cardiovascular disease, and treatment feasibility among others. We reviewed pivotal first-line systemic therapy trials, complemented by key real-world cohorts evaluating outcomes in underrepresented populations. A targeted literature search was undertaken using PubMed/Medline and major oncology/hepatology meeting proceedings to identify prospective trials, guideline statements, and representative real-world studies focused on patient-level prognostic factors (Child-Pugh, ALBI), portal hypertension/varices, portal vein tumor thrombosis, cardiovascular risk, autoimmune disease, and transplant settings. We synthesize these data into a pragmatic framework to guide personalized regimen selection and improve prognostication in advanced HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.